NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
Rhea-AI Summary
NervGen (TSXV:NGEN, NASDAQ:NGEN) announced that Chief Financial Officer Bill Adams will retire effective March 15, 2026. The company has engaged an executive search firm to find a successor, and Mr. Adams will remain in an advisory capacity to support the transition.
The release notes Mr. Adams served six years and highlights NervGen's progression to a Nasdaq-listed company advancing NVG-291 into late-stage development.
Positive
- CFO transition planned with advisory support through March 15, 2026
- Company has engaged a leading executive search firm to identify a successor
- NervGen advancing NVG-291 into late-stage development (company milestone)
- CFO served six years, providing leadership continuity during transition
Negative
- Departure of CFO may create near-term leadership uncertainty in finance
- Successor timeline unknown — potential operational disruption until hire completes
News Market Reaction – NGEN
On the day this news was published, NGEN gained 2.43%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition.
“On behalf of the Board of Directors and our NervGen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to the Company,” said Adam Rogers, MD, President and Chief Executive Officer of NervGen. “Bill joined us at a critical moment in the lifecycle of the Company six years ago and has been a trusted colleague and advisor. His integrity, thoughtfulness, and commitment to our mission have been invaluable to me personally and to the entire organization. We're grateful for everything Bill has contributed to NervGen and wish him the best in a well-deserved retirement.”
“I am honored to have served as Chief Financial Officer of NervGen and to have played a meaningful role in all that we’ve accomplished over the past several years,” Mr. Adams commented. “It gives me great joy to have helped guide the Company’s dramatic transformation from preclinical and first-in-human studies to a Nasdaq-listed company entering late-stage development for NVG-291, a therapeutic candidate with the potential to significantly impact the lives of so many around the world living with spinal cord injury.”
“These past six years at NervGen has been unlike anything else I’ve had the opportunity to work on in my career, and I’m incredibly proud of the financial and operational foundation we’ve built. I believe the Company is well positioned, with a clear path ahead. I look forward to supporting NervGen during this transition and cheering on its continued success in the years to come,” Mr. Adams concluded.
About NervGen Pharma
NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life. The Company’s Phase 1b/2a CONNECT SCI Study in individuals with subacute SCI is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
Contacts
Huitt Tracey, Investors
htracey@nervgen.com
604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310
Adam Rogers, President and CEO
info@nervgen.com
778.731.1711
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note and Forward Looking-Statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Such forward-looking statements herein include but are not limited to, the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “trend”, “indication”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company's plans to engage and appoint a successor CFO; the expected timing and nature of the CFO transition; Mr. Adams' continued support in an advisory capacity; the Company’s potentially best-in-class candidate, NVG-291; the potential broad therapeutic applications of NVG-291; the future growth of the Company; the Company’s mission to transform the lives of individuals living with spinal cord injury; the Company’s pursuit to revolutionize the treatment paradigm for neurotraumatic conditions with significant unmet medical need; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and final results from our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; and the creation of neuroreparative therapeutics to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company’s actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company’s most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen’s profile on SEDAR+ at www.sedarplus.ca and in NervGen’s Form F-10/A filed on EDGAR at www.edgar.com. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
FAQ
When will NervGen (NGEN) CFO Bill Adams officially retire?
Will Bill Adams stay involved with NervGen (NGEN) after March 15, 2026?
How long did Bill Adams serve as NervGen (NGEN) CFO before retiring?
What steps is NervGen (NGEN) taking to replace the retiring CFO?
Does Bill Adams' retirement affect NervGen's NVG-291 development timeline?
